Pyrvinium pamoate regulates MGMT expression through suppressing the Wnt/β-catenin signaling pathway to enhance the glioblastoma sensitivity to temozolomide
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Temozolomide (TMZ) is the mainstream chemotherapeutic drug for treating glioblastoma multiforme (GBM), but the intrinsic or acquired chemoresistance to TMZ has become the leading clinical concern, which is related to the repair of DNA alkylation sites by O 6-methylguanine-DNA methyltransferase (MGMT). Pyrvinium pamoate (PP), the FDA-approved anthelminthic drug, has been reported to inhibit the Wnt/β-catenin pathway within numerous cancer types, and Wnt/β-catenin signaling pathway can modulate the expression of MGMT gene. However, whether PP affects the expression of MGMT and enhances TMZ sensitivity in GBM cells remains unclear. In the present study, we found that PP and TMZ had synergistic effect on inhibiting the viability of GBM cells, and PP induced inhibition of MGMT and enhanced the TMZ chemosensitivity of GBM cells through down-regulating Wnt/β-catenin pathway. Moreover, the overexpression of MGMT or β-catenin weakened the synergy between PP and TMZ. The mechanism of PP in inhibiting the Wnt pathway was indicated that PP resulted in the degradation of β-catenin via the AKT/GSK3β/β-catenin signaling axis. Moreover, Ser552 phosphorylation in β-catenin, which promotes its nuclear accumulation and transcriptional activity, is blocked by PP that also inhibits the Wnt pathway to some extent. The intracranial GBM mouse model also demonstrated that the synergy between PP and TMZ could be achieved through down-regulating β-catenin and MGMT, which prolonged the survival time of tumor-bearing mice. Taken together, our data suggest that PP may serve as the prospect medicine to improve the chemotherapeutic effect on GBM, especially for chemoresistant to TMZ induced by MGMT overexpression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 The underlying mechanism of PP in regulating β-catenin. A The protein levels of AKT, p-AKT, GSK3β, p-GSK3β (S9), p-GSK3β (Y216), p-β-catenin (S552), and p-β-catenin (S33/37/T41) were evaluated through western blotting following PP treatment at different contents. B Effect of pretreatment with GSK3β inhibitor CHIR-99021 on PP-induced β-catenin down-regulation (top panel). Densitometric analysis of β-catenin/β-actin expression fold change (bottom panel). C Schematic diagram for the underlying mechanism by which PP regulated β-catenin. PP inhibits the activation of AKT, thereby increasing the activity of GSK3β, leading to increased degradation of β-catenin by multi-protein destruction complex, which mainly includes Axin, APC, and GSK-3β. β-catenin has at least two distinct pools. One is located in cytoplasm which binds with E-cadherin, and the other one is involved in the Wnt signaling pathway so that shuttles between cytoplasm and nucleus [45]. AKT mediates the phosphorylation of β-catenin associated with plasma membrane, and then induces the dissociation of β-catenin from E-cadherin, which accumulates in cytoplasm and nucleus [30]. In the case of PP addition, PP reduces the p-AKT protein level and further down-regulates p-β-catenin (S552) expression in the cells. Consequently, dissociation of β-catenin from E-cadherin within cell membrane is reduced, so that the combination of β-catenin with the LEF/TCF transcription factors in cell nucleus is reduced, either, which hinders the activation of MGMT gene. *p < 0.05; **p < 0.01; ***p < 0.005.](https://figures.cochat.ai/paper-figures/63437b1b783a4deb85821f44b0c193c8/pyrvinium-pamoate-regulates-mgmt-expression-through-suppressing-the-wnt-catenin-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the key regulators of PDAC metastasis is the Wnt/β‐catenin pathway.”
From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models (2024) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon activation, this pathway leads to the translocation of β‐catenin into the nucleus where it facilitates the transcription of genes that induce EMT, invasion and migration to distant sites [41, 42]”
From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models (2024) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“PP is a well‐known inhibitor of the Wnt/β‐catenin pathway [41, 43]”
From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models (2024) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Fukai, J., Koizumi, F., & Nakao, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104538 · Cited by 24
RetractedDrug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Glioblastoma and Other Malignant Gliomas: A Clinical Review
Omuro, A. (2013) · JAMA · doi:10.1001/jama.2013.280319 · Cited by 2,301
WNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3419 · Cited by 1,911
The many faces and functions of β‐catenin
Valenta, T., Hausmann, G., & Basler, K. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.150 · Cited by 1,598
Phosphorylation of β-Catenin by AKT Promotes β-Catenin Transcriptional Activity
Fang, D., Hawke, D., Zheng, Y., Xia, Y., Meisenhelder, J., Nika, H., Mills, G. B., Kobayashi, R., Hunter, T., & Lu, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611871200 · Cited by 870
Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death.
Korsmeyer, S. J., Shutter, J. R., Novack, D. V., Merry, D. E., & Oltvai, Z. N. (1993) · PubMed · Cited by 865
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Di Veroli, G. Y., Fornari, C., Wang, D., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 736
The regulation of β-catenin activity and function in cancer: therapeutic opportunities
Shang, S., Hua, F., & Hu, Z.-W. (2017) · Oncotarget · doi:10.18632/oncotarget.15687 · Cited by 641
MGMT testing—the challenges for biomarker-based glioma treatment
Wick, W., Weller, M., van den Bent, M., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 579
Liang, W.-C., Wong, C.-W., Liang, P.-P., Shi, M., Cao, Y., Rao, S.-T., Tsui, S. K.-W., Waye, M. M.-Y., Zhang, Q., Fu, W.-M., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1685-4 · Cited by 493
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
JIAPAER, S., FURUTA, T., TANAKA, S., KITABAYASHI, T., & NAKADA, M. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0141 · Cited by 324
High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses.
Shen, L., Niu, J., Wang, C., Huang, B., Wang, W., Zhu, N., Deng, Y., Wang, H., Ye, F., Cen, S., et al. (2019) · Journal of Virology · doi:10.1128/jvi.00023-19 · Cited by 319
Temozolomide for immunomodulation in the treatment of glioblastoma
Karachi, A., Dastmalchi, F., Mitchell, D. A., & Rahman, M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy072 · Cited by 300
Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A., Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B. D., et al. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 292
WNT signaling in glioblastoma and therapeutic opportunities
Lee, Y., Lee, J.-K., Ahn, S. H., Lee, J., & Nam, D.-H. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2015.140 · Cited by 273
Xing, Y., Clements, W. K., Kimelman, D., & Xu, W. (2003) · Genes & Development · doi:10.1101/gad.1142603 · Cited by 237
Nucleo-cytoplasmic distribution of β-catenin is regulated by retention
Krieghoff, E., Behrens, J., & Mayr, B. (2006) · Journal of Cell Science · doi:10.1242/jcs.02864 · Cited by 236
Wickström, M., Dyberg, C., Milosevic, J., Einvik, C., Calero, R., Sveinbjörnsson, B., Sandén, E., Darabi, A., Siesjö, P., Kool, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9904 · Cited by 229
Perazzoli, G., Prados, J., Ortiz, R., Caba, O., Cabeza, L., Berdasco, M., Gónzalez, B., & Melguizo, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140131 · Cited by 198
Regulation of the G1 phase of the mammalian cell cycle
DONJERKOVIC, D., & SCOTT, D. W. (2000) · Cell Research · doi:10.1038/sj.cr.7290031 · Cited by 190
Yong, X., Tang, B., Xiao, Y.-F., Xie, R., Qin, Y., Luo, G., Hu, C.-J., Dong, H., & Yang, S.-M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.032 · Cited by 174
Is β-Catenin a Druggable Target for Cancer Therapy?
Cui, C., Zhou, X., Zhang, W., Qu, Y., & Ke, X. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.06.003 · Cited by 168
Yi, G.-Z., Huang, G., Guo, M., Zhang, X., Wang, H., Deng, S., Li, Y., Xiang, W., Chen, Z., Pan, J., et al. (2019) · Brain · doi:10.1093/brain/awz202 · Cited by 165
Self-citationAKT/GSK3β Signaling in Glioblastoma
Majewska, E., & Szeliga, M. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2044-4 · Cited by 144
Wnt/beta-Catenin Signaling in Glioma
Zhang, K., Zhang, J., Han, L., Pu, P., & Kang, C. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9359-y · Cited by 141
Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling
Nikolova, T., Roos, W. P., Krämer, O. H., Strik, H. M., & Kaina, B. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.004 · Cited by 97
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors
Jackson, C. B., Noorbakhsh, S. I., Sundaram, R. K., Kalathil, A., Ganesa, S., Jia, L., Breslin, H. J., Burgenske, D. M., Gilad, O., Sarkaria, J. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3394 · Cited by 85
Tomar, V. S., Patil, V. S., & Somasundaram, K. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09502-7 · Cited by 79
The novel role of pyrvinium in cancer therapy
Momtazi‐borojeni, A. A., Abdollahi, E., Ghasemi, F., Caraglia, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26006 · Cited by 75
Cell death-based treatment of glioblastoma
Fulda, S. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0021-8 · Cited by 74
Lan, F., YANG, Y., Han, J., Wu, Q., Yu, H., & Yue, X. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3271 · Cited by 71
Chen, Y., Fang, R., Yue, C., Chang, G., Li, P., Guo, Q., Wang, J., Zhou, A., Zhang, S., Fuller, G. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1229 · Cited by 71
Self-citationZhang, C., Zhang, Z., Zhang, S., Wang, W., & Hu, P. (2017) · Medical Science Monitor · doi:10.12659/msm.901667 · Cited by 70
Threonine 41 in β-Catenin Serves as a Key Phosphorylation Relay Residue in β-Catenin Degradation
Wu, G., & He, X. (2006) · Biochemistry · doi:10.1021/bi0601149 · Cited by 68
The Kinetics of G2 and M Transitions Regulated by B Cyclins
Huang, Y.-H., Sramkoski, R. M., & Jacobberger, J. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080861 · Cited by 63
Repurposing drugs for glioblastoma: From bench to bedside
Basso, J., Miranda, A., Sousa, J., Pais, A., & Vitorino, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.039 · Cited by 63
Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells
Venugopal, C., Hallett, R. M., Vora, P., Manoranjan, B., Mahendram, S., Qazi, M. A., McFarlane, N., Subapanditha, M., Nolte, S. M., Singh, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3147 · Cited by 63
Yang, W., Wu, P.-F., Ma, J., Liao, M., Wang, X., Xu, L., Xu, M., & Liang, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1449-9 · Cited by 60
Du, L., Wang, C., Meng, L., Cheng, Q., Zhou, J., Wang, X., Zhao, D., Zhang, J., Deng, L., Liang, Z., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.046 · Cited by 58
Chen, C., Zhu, D., Zhang, H., Han, C., Xue, G., Zhu, T., Luo, J., & Kong, L. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0645-3 · Cited by 53
Bi, Y., Han, L., Yi, D., Bai, Y., Zhong, S., Liu, Q., Chen, Y., & Zhao, G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.040 · Cited by 52
Self-citationSokolosky, M., Chappell, W. H., Stadelman, K., Abrams, S. L., Davis, N. M., Steelman, L. S., & McCubrey, J. A. (2014) · Cell Cycle · doi:10.4161/cc.27728 · Cited by 51
Identification of two novel regulated serines in the N terminus of beta-catenin.
van Noort, M., Wetering, M. L. V. D., & Clevers, H. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5520 · Cited by 48
Datta, S., Sears, T. K., Cortopassi, G. A., Woolard, K., & Angelastro, J. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111058 · Cited by 40
Khan, M., Muzumdar, D., & Shiras, A. (2018) · Neoplasia · doi:10.1016/j.neo.2018.11.005 · Cited by 39
Moon, B.-S., Cai, M., Lee, G., Zhao, T., Song, X., Giannotta, S. L., Attenello, F. J., Yu, M., & Lu, W. (2020) · Journal of Clinical Investigation · doi:10.1172/jci127916 · Cited by 36
Identification of FDA-Approved Drugs with Activity against Stationary Phase Bartonella henselae
Li, T., Feng, J., Xiao, S., Shi, W., Sullivan, D. J., & Zhang, Y. (2019) · Antibiotics · doi:10.3390/antibiotics8020050 · Cited by 29
Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and induces apoptosis in multiple myeloma cells
Xu, F., Zhu, Y., Lu, Y., Yu, Z., Zhong, J., Li, Y., & Pan, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8006 · Cited by 26
Self-citationZinc and Iron Homeostasis: Target-Based Drug Screening as New Route for Antifungal Drug Development
Simm, C., & May, R. C. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00181 · Cited by 26
Zheng, L., Liu, Y., & Pan, J. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx089 · Cited by 23
Barbarino, M., Cesari, D., Intruglio, R., Indovina, P., Namagerdi, A. A., Bertolino, F. M., Bottaro, M., Rahmani, D., Bellan, C., & Giordano, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26579 · Cited by 23
Wang, Z., Dai, Z., Luo, Z., & Zuo, C. (2019) · Molecules · doi:10.3390/molecules24132391 · Cited by 20
Direct interaction of menin leads to ubiquitin-proteasomal degradation of β-catenin
Kim, B., Song, T.-Y., Jung, K. Y., Kim, S. G., & Cho, E. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.08.011 · Cited by 18
Cui, L., Zhao, J., & Liu, J. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.11.017 · Cited by 17
Li, Z., Zhou, L., Jiang, T.-X., Fan, L., Liu, X., & Qiu, X. (2019) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy176 · Cited by 12
β-Catenin accumulation and S33F mutation of CTNNB1 gene in colorectal cancer in Saudi Arabia
Alomar, S. Y., Mansour, L. A., Abuderman, A., ALKHURIJI, A. F., Arafah, M., Alwasel, S. H., Harrath, A. H., Almutairi, M. H., Trayhyrn, P., & Dar, J. A. (2016) · Polish Journal of Pathology · doi:10.5114/pjp.2016.61452 · Cited by 11
Chen, T. C., Chan, N., Minea, R. O., Hartman, H., Hofman, F. M., & Schönthal, A. H. (2018) · Cancers · doi:10.3390/cancers10100362 · Cited by 10
Wingless/β-catenin signaling as a modulator of chemoresistance in cancer
Johnsen, J. I., Wickström, M., & Baryawno, N. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1131356 · Cited by 10
Pyrvinium pamoate inhibits proliferation and invasion of human endometriotic stromal cells
Karamian, A., Nazarian, H., Ziai, S. A., Zarnani, A. H., Salehpour, S., Paktinat, S., & Novin, M. (2019) · Human & Experimental Toxicology · doi:10.1177/0960327119896612 · Cited by 8
Research works printed but not linked: 1
- Zheng L Liu Y Pan J Inhibitory effect of pyrvinium pamoate on uveal melanoma cells involves blocking of Wnt/β-catenin pathway Acta Biochim Biophys Sin 2017 49 890 8 10.1093/abbs/gmx089 28981601 · DOI
Cited by
Zhao, X., Ma, Y., Luo, J., Xu, K., Tian, P., Lu, C., & Song, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35989 · Cited by 66
“It has been also found that Pyrvinium enhances the sensitivity of glioblastoma to temozolomide by suppressing the WNT/ β -catenin pathway [75].”
BackgroundPyrvinium Pamoate: Past, Present, and Future as an Anti-Cancer Drug
Schultz, C. W., & Nevler, A. (2022) · Biomedicines · doi:10.3390/biomedicines10123249 · Cited by 44
Modulating MGMT expression through interfering with cell signaling pathways
Bai, P., Fan, T., Wang, X., Zhao, L., Zhong, R., & Sun, G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115726 · Cited by 39
Pond, K. W., Morris, J. M., Alkhimenok, O., Varghese, R. P., Cabel, C. R., Ellis, N. A., Chakrabarti, J. L., Zavros, Y. L., Merchant, J. L., Thorne, C. A., et al. (2022) · eLife · doi:10.7554/elife.78837 · Cited by 34
Epigenetic regulation of tumor-immune symbiosis in glioma
Liu, Y., Ali, H. A., Khan, F., Pang, L., & Chen, P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.02.004 · Cited by 29
Metadata
- Authors
- Li, H., Liu, S., Jin, R., Xu, H., Li, Y., Chen, Y., & Zhao, G.
- Affiliations
- First Hospital of Jilin University (CN)
- Corresponding author
- Chen, Yong
- Zhao, Gang
- Venue
- Cell Death Discovery
- Published
- 2021-10-12
- Volume
- 7
- Issue
- 1
- Pages
- 288-288
- ISSN
- 2058-7716 (ISSN-L)
- PMC
- PMC8511032
- OpenAlex
- W3205428234
- Cited by
- 34
- References
- 63
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 10 · 2023: 6 · 2022: 4 · 2021: 1
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death Discovery (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- People's Government of Jilin Province
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- pyrvinium pamoate, glioblastoma, temozolomide, MGMT, Wnt/β-catenin signaling, drug repurposing, chemosensitization, chemoresistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.